An observational study in Dentin Hypersensitivity, sponsored by HALEON. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by HALEON · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Dentin Sensitivity by HALEON — 3 open to participants now, 3 under way, none of them phase 3. Dentin Sensitivity · HALEON.
Among the 21 studies in Dentin Sensitivity by HALEON, this one is one of 4 that started in 2025, is the only observational one, and was the 15th registered.
291 studies on the registry are indexed under Dentin Sensitivity; 49 are open to participants now.
Browse Dentin Sensitivity studies →3 of the 21 studies in Dentin Sensitivity by HALEON are open now, in 3 countries. Recruiting first, the newest first:
HALEON · Sites in Canada
Ages 18+ · Healthy volunteers
HALEON · Sites in United Kingdom
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 20 Dentin Sensitivity studies recruiting now, 6 (30%) set no upper age limit and 13 (65%) stop at 75 or younger; 2 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2025.
Median enrollment 185 across the 20 interventional studies, 375 across the 1 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
3 of the studies in Dentin Sensitivity by HALEON that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07894796HALEONA Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity | 2027-01 |
| NCT07337109HALEONA Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers | 2027-02 |
| NCT07802886HALEONA Clinical Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Dentin Sensitivity by HALEON, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to characterize changes in Oral-Health-Related Quality of Life (OHrQoL), as measured by the Dentin Hypersensitivity Experience Questionnaire (DHEQ) over a 12-month period.
This will be a longitudinal study investigating OHrQoL and treatment patterns amongst new sufferers of self-reported Dentin Hypersensitivity (DH). Over the 12-month study duration, 375 participants suffering from DH will complete questionnaires online once per month.
Participants who are new sufferers of DH and have begun treating their DH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant whose sensitivity could be caused by other factors or clinical pathology than DH, as self-reported on the screening questionnaire, which include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change From Baseline in Total DHEQ Score Over 12 Months
Change from baseline in total DHEQ score and each of the domain scores (daily restrictions, coping behaviors, personal identity, social impact, emotional impact) over 12 months. The DHEQ has total 15 questions each will be scored on a scale ranging from 1 (strongly disagree) to 7 (strongly agree), thus total possible score will be ranging from 15 to 105, where higher score indicates worst outcome.
Time frame: Baseline and up to 12 Months
Description of Treatment Selection Over 12 Months
Participants will select the appropriate options from the given list of products. Data will be summarized using descriptive statistics.
Time frame: Up to 12 Months
Treatment Discontinuation/Switch Over 12 Months
Participant will respond to the question either as Yes or No. Data will be summarized using descriptive statistics.
Time frame: Up to 12 Months
Frequency of Treatment Used Over 12 Months
Participants will select the appropriate frequency options from the given list. Data will be summarized using descriptive statistics.
Time frame: Up to 12 Months
Frequency of DH Over 12 Months
Participants will select the appropriate frequency options from the given list. Data will be summarized using descriptive statistics.
Time frame: Up to 12 Months
Frequency of Brushing at Baseline, Months 6 and 12
Participants will select the appropriate frequency options from the given list. Data will be summarized using descriptive statistics.
Time frame: Baseline, Months 6 and 12
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Feb 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.